Medico Remedies Limited has announced its unaudited standalone financial results for the third quarter of FY26, showcasing strong operational performance across key financial metrics. The pharmaceutical formulation manufacturer reported significant growth in both revenue and profitability for the quarter ended December 31, 2025.

Financial Performance Highlights

The company's financial performance for Q3 FY26 demonstrated robust growth momentum. Revenue from operations reached ₹5,868.29 lakhs, representing a substantial 48.6% increase from ₹3,948.99 lakhs recorded in Q3 FY25. This strong revenue growth was accompanied by improved profitability, with net profit after tax reaching ₹287.23 lakhs compared to ₹261.97 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Medico Remedies maintained its growth trajectory with impressive year-over-year improvements. Total revenue from operations reached ₹14,956.96 lakhs, marking a 36.4% increase from ₹10,963.74 lakhs in the corresponding period of FY25. The company's net profit for the nine-month period stood at ₹725.86 lakhs, representing a 26.2% growth compared to ₹575.24 lakhs in the previous year.

Operational Efficiency and Cost Management

The company's operational metrics reflect effective cost management strategies. Total expenses for Q3 FY26 amounted to ₹5,552.74 lakhs compared to ₹3,741.70 lakhs in Q3 FY25. Cost of materials consumed represented the largest expense component at ₹3,618.44 lakhs, while employee benefits expense stood at ₹212.92 lakhs. The company maintained healthy profit margins with profit before tax reaching ₹383.23 lakhs for the quarter.

Geographic Revenue Distribution

Medico Remedies demonstrated strong international presence with export sales significantly outpacing domestic revenue. For Q3 FY26, sales of products outside India reached ₹5,156.03 lakhs, while domestic sales contributed ₹689.73 lakhs. This export-focused business model highlights the company's competitive positioning in international pharmaceutical markets.

Corporate Governance and Compliance

The financial results were reviewed by the audit committee and approved by the Board of Directors at their meeting held on February 12, 2026. The results have been subjected to limited review by statutory auditors Shah Shroff & Associates, who issued an unmodified report on the unaudited financial results. The company maintains its paid-up equity share capital at ₹1,659.68 lakhs with a face value of ₹2 per share.

Medico Remedies Limited has secured a substantial government supply order worth ₹37,17,62,439 from Uttar Pradesh Medical Supplies Corporation Limited, as disclosed under Regulation 30 of the SEBI Listing Regulations. The pharmaceutical manufacturer announced this development on January 26, 2026, highlighting a significant business milestone for the company.

Order Details and Scope

The contract involves supplying multiple drugs to Uttar Pradesh Medical Supplies Corporation Limited, an entity formed by the Government of Uttar Pradesh. This corporation serves as the centralized procurement and distribution hub for medicines and health supplies across the state, ensuring timely and effective healthcare services to the people of Uttar Pradesh.

Contract Terms and Timeline

The company has committed to completing the full order supply by October 31, 2026, providing a clear execution timeline for this government contract. The order falls under domestic entity classification, strengthening Medico Remedies' position in the government healthcare supply sector.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with sub-para 4, Part B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that:

• No promoter, promoter group, or group companies have any interest in the awarding entity
• The transaction does not fall within related party transactions
• All terms and conditions are as per the contract specifications

Company Background

Medico Remedies Limited operates as a WHO-GMP and ISO 9001-2015 certified pharmaceutical formulations manufacturer. The company holds the distinction of being a government-recognized star export house, demonstrating its established credentials in pharmaceutical manufacturing and supply. Based in Mumbai, the company specializes in manufacturing pharmaceutical formulations and maintains multiple digital platforms for business operations.

This government order represents a significant addition to Medico Remedies' business portfolio, reinforcing its capabilities in large-scale pharmaceutical supply operations and government sector engagement.